Protective effect of hydroxysafflor yellow A on cyclosporin A-induced renal oxidative stress in vitro and in vivo

Purpose: To explore the mechanism and investigate the protective effect of hydroxysafflor yellow A (HSYA) on renal oxidative stress, which cyclosporine A (CsA) induces. Methods: HK-2 cells were treated with CsA to get CsA-induced oxidative stress. The effects on oxidative stress and apoptosis of HK-2 cells were detected. The contents of SOD, MDA, GSH-Px, ROS, and CAT in serum were measured, and the expression of apoptosis-related proteins was detected by western blot. Then, established the renal oxidative stress injury rats to verify the efficacy of HSYA. Results: HSYA could reduce the ROS and MDA contents induced by CsA. Compared with the CsA group, the activities of SOD, CAT, and GSH-Px increased significantly when treated with HSYA. HSYA could inhibit CsA-induced apoptosis in HK-2 cells, and promote the protein of Bcl-2 and inhibit the expression of Bax. Animal experiments showed that HSYA could reduce CsA-induced renal cell injury by reducing glomerular cell vacuoles and inflammatory factors in tissues. It also decreased serum creatinine (Crea) and blood urea nitrogen, increased Crea clearance significantly. Conclusions: HSYA could significantly improve the antioxidant capacity of the kidney cells and inhibit cell apoptosis, thereby effectively ameliorating CsA-induced oxidative stress in vitro and in vivo.

Cyclosporine reduces the spleen dimensions in rabbits

Purpose To assess the influence of prolonged cyclosporine use on the macro- and microscopic morphology of the spleen. Methods 16 adult rabbits were divided into two groups (n = 8): group 1 a placebo group, which was followed-up over a period of nine months; group 2 which had taken an oral dose of cyclosporine (10 mg·kg1·day1) over nine months. At the end of this period, the splenic histoarchitecture of all animals was evaluated and the splenic corpuscles were measured. Results The spleens of the first group presented normal characteristics and dimensions. The second group, however, had a reduction in all dimensions and its tissue texture had become soft. The white pulp and the perivascular sheath had become reduced in size and the number of lymphoid follicles had also fallen (p = 0.002), manifesting less splenic corpuscles (p = 0.0012) and lymphocyte nuclear pigments (p = 0.03). Conclusions Prolonged use of cyclosporine reduces the spleen size, transforming it into a soft organ associated with a decrease in white pulp, perivascular sheath, lymphoid follicles and nuclear pigments in rabbits.(AU)

Eosinophilic cystitis, a rare cause of persistent haematuria in a diabetic dog / Cistite eosinofílica, uma causa rara de hematúria persistente em um cão diabético

Eosinophilic cystitis is a rare inflammatory disorder characterized by eosinophilic infiltration of entire layers of the bladder wall. The condition has been described in adults, children, and dogs. However, there are no consensus guidelines for the treatment of eosinophilic cystitis. Although human and veterinary literature reviews show some effectiveness in management with corticosteroids, antihistamines, and antibiotics, a variety of serious and frequent side effects are associated with steroid therapy. As a result, steroids are relatively contraindicated for patients with diabetes mellitus and Cushing's syndrome. A five-year-old neutered male chow-chow with controlled diabetes was referred with an 18-month history of malodorous urine, gross haematuria, and dysuria that were nonresponsive to antibiotics. The findings on general examination were unremarkable except for abdominal suprapubic discomfort. The complete blood count and biochemical profile (such as urea and creatinine) were normal except for mild peripheral eosinophilia. Although ultrasonography, bladder contrast radiography, and urine cytology findings indicated malignancy, with the presence of atypical urothelial cells, histopathology confirmed eosinophilic cystitis. Management with cyclosporine was adequate with complete remission of haematuria. This case report presents the first reported successful use of cyclosporine for the treatment of eosinophilic cystitis in a dog with diabetes.(AU)

A cistite eosinofílica é uma doença inflamatória rara caracterizada por infiltração eosinofílica de todas as camadas da parede da bexiga. Essa enfermidade já foi descrita em adultos, crianças e cães. No entanto, não há um consenso de diretrizes sobre o seu tratamento. Mesmo que as literaturas humana e veterinária mostrem alguma eficácia no manejo com corticosteroides, anti-histamínicos e antibióticos, uma variedade de efeitos colaterais graves e frequentes está associada à terapia com esteroides. Dessa forma, o uso de esteroides é relativamente contraindicado para pacientes com diabetes mellitus e síndrome de Cushing, por exemplo. Um chow-chow, macho, castrado, de cinco anos e diabético estável foi encaminhado para atendimento com histórico de urina fétida, hematúria macroscópica e disúria não responsiva a antibióticos há 18 meses. A avaliação dos parâmetros físicos estava dentro dos padrões, exceto por desconforto abdominal suprapúbico à palpação. O hemograma e o perfil bioquímico (como a ureia e a creatinina) estavam dentro da normalidade para a espécie, exceto por eosinofilia periférica leve. Embora a ultrassonografia, a radiografia contrastada da bexiga e os achados da urinálise indicassem malignidade, com a presença de células uroteliais atípicas, a histopatologia confirmou o diagnóstico definitivo de cistite eosinofílica. O manejo com ciclosporina foi satisfatório, com ausência completa da hematúria. Este relato de caso apresenta o primeiro uso documentado de ciclosporina para o tratamento de cistite eosinofílica com sucesso em um cão com diabetes.(AU)

Eosinophilic cystitis, a rare cause of persistent haematuria in a diabetic dog / Cistite eosinofílica, uma causa rara de hematúria persistente em um cão diabético

Eosinophilic cystitis is a rare inflammatory disorder characterized by eosinophilic infiltration of entire layers of the bladder wall. The condition has been described in adults, children, and dogs. However, there are no consensus guidelines for the treatment of eosinophilic cystitis. Although human and veterinary literature reviews show some effectiveness in management with corticosteroids, antihistamines, and antibiotics, a variety of serious and frequent side effects are associated with steroid therapy. As a result, steroids are relatively contraindicated for patients with diabetes mellitus and Cushing's syndrome. A five-year-old neutered male chow-chow with controlled diabetes was referred with an 18-month history of malodorous urine, gross haematuria, and dysuria that were nonresponsive to antibiotics. The findings on general examination were unremarkable except for abdominal suprapubic discomfort. The complete blood count and biochemical profile (such as urea and creatinine) were normal except for mild peripheral eosinophilia. Although ultrasonography, bladder contrast radiography, and urine cytology findings indicated malignancy, with the presence of atypical urothelial cells, histopathology confirmed eosinophilic cystitis. Management with cyclosporine was adequate with complete remission of haematuria. This case report presents the first reported successful use of cyclosporine for the treatment of eosinophilic cystitis in a dog with diabetes.(AU)

A cistite eosinofílica é uma doença inflamatória rara caracterizada por infiltração eosinofílica de todas as camadas da parede da bexiga. Essa enfermidade já foi descrita em adultos, crianças e cães. No entanto, não há um consenso de diretrizes sobre o seu tratamento. Mesmo que as literaturas humana e veterinária mostrem alguma eficácia no manejo com corticosteroides, anti-histamínicos e antibióticos, uma variedade de efeitos colaterais graves e frequentes está associada à terapia com esteroides. Dessa forma, o uso de esteroides é relativamente contraindicado para pacientes com diabetes mellitus e síndrome de Cushing, por exemplo. Um chow-chow, macho, castrado, de cinco anos e diabético estável foi encaminhado para atendimento com histórico de urina fétida, hematúria macroscópica e disúria não responsiva a antibióticos há 18 meses. A avaliação dos parâmetros físicos estava dentro dos padrões, exceto por desconforto abdominal suprapúbico à palpação. O hemograma e o perfil bioquímico (como a ureia e a creatinina) estavam dentro da normalidade para a espécie, exceto por eosinofilia periférica leve. Embora a ultrassonografia, a radiografia contrastada da bexiga e os achados da urinálise indicassem malignidade, com a presença de células uroteliais atípicas, a histopatologia confirmou o diagnóstico definitivo de cistite eosinofílica. O manejo com ciclosporina foi satisfatório, com ausência completa da hematúria. Este relato de caso apresenta o primeiro uso documentado de ciclosporina para o tratamento de cistite eosinofílica com sucesso em um cão com diabetes.(AU)

Effects of cyclosporine on ischemia-reperfusion injuries in rat kidneys. An experimental model

Abstract Purpose To assess Cyclosporine A (CsA) therapy at an intraperitoneal dose of 15 mg.kg -1 in a rodent model of non-septic renal ischemia. Methods Twenty male Wistar rats were randomized to receive CsA therapy or none therapy before undergoing 30 minutes of renal ischemia followed by reperfusion. Additionally, 10 rats were randomized to undergo the same surgical procedure of the aforementioned animals with neither ischemia nor CsA therapy. Twelve hours after kidney ischemia, the left kidneys were evaluated for histological injury according to Park's criteria. Serum creatinine (Cr), urea nitrogen (Ur) and sodium levels were obtained at different times of the experimental protocol. Results Rodents in the CsA group showed negative results (p<0.05) in serum variables (Cr: 0.41±0.05mg/dL vs . 4.17±1.25mg/dL; Ur: 40.90±3.98mg/dL vs . 187.70±22.93mg/dL) even the non CsA or control group (Cr: 0.35±0.07mg/dL vs . 3.80±1.20mg/dL; Ur: 40.10±4.70mg/dL vs . 184.50±49.80mg/dL). The negative results were also verified in histological evaluation, CsA group had 50% in the very severe grade of lesion, 10% in the severe and 40% in the moderate to severe whereas the control group had 90% in the very severe grade. Conclusion CsA was incapable of preventing the deleterious effects of ischemia-reperfusion injury in rat kidneys.(AU)

Eficácia dos colírios ciclosporina e tacrolimo no tratamento de ceratoconjuntivite seca em cães / Efficacy of cyclosporine and tacrolimus drops in the treatment of keratoconjunctivitis sicca in dogs

O objetivo deste estudo foi avaliar os efeitos do tacrolimo e da ciclosporina na produção lacrimal de cães com ceratoconjuntivite seca (CCS) durante 90 dias. Para tanto, foram utilizados colírios de tacrolimo 0,02% (TcL) e ciclosporina 0,1% (CsA) em 14 cães com CCS. Os animais foram distribuídos em dois grupos e avaliados antes do início do tratamento (T0) e aos 15 (T1), 30 (T2), 45 (T3), 60 (T4), 75 (T5) e 90 (T6) dias após o início do tratamento. Na avaliação clínica, observou-se maior redução da secreção ocular, da opacidade e do edema corneano e da vascularização conjuntival. no grupo tacrolimo. No teste de Schirmer, verificou-se produção basal de 6(4,07 e 5,86(2,85mm/min no TcL e CsA, respectivamente, com aumento significativo da produção lacrimal em ambos os grupos, contudo houve aumento significativo da produção lacrimal a partir dos 15 dias de tratamento no grupo TcL (17,88(5,51mm/min), mas apenas a partir dos 45 dias no grupo CsA (11,86(4,74mm/min). Conclui-se que o uso do colírio tacrolimo aumentou em 68,83% a produção lacrimal em 90 dias de tratamento, comparado com a ciclosporina (56,82%), além de diminuir as manifestações clínicas inerentes à CCS, quando comparado à terapia com ciclosporina.(AU)

The objective of this study was to evaluate the effects of tacrolimus and cyclosporine on the lacrimal production of dogs with ketaroconjunctivitis sicca (KCS) for 90 days. Tacrolimus 0.02% (TcL) and 0.1% cyclosporine (CsA) eye drops were used in 14 dogs with KCS. The animals were randomly assigned to two groups and evaluated before treatment (T0) and at 15 (T1), 30 (T2), 45 (T3), 60 (T4), 75 (T5) and 90 (T6) days after initiation of treatment. Clinical evaluation showed significant reduction of ocular secretion, corneal opacity and edema and conjunctival vascularization in the tacrolimus group. Schirmer test showed basal lacrimal production of 6(4.07 and 5.86(2.85mm/min for TcL and CsA, respectively, with significant increase in lacrimal production in both groups. There was a significant increase in lacrimal production after 15 days of treatment in the TcL group (17.88(5.51mm/min), but only after 45 days in the CsA group (11.86(4.74mm/min). Tacrolimus drops increased lacrimal production in 68.83% after 90 days of treatment, compared to cyclosporine (56.82%), and also reduced clinical manifestations related to KCS when compared to cyclosporine.(AU)

Eficácia dos colírios ciclosporina e tacrolimo no tratamento de ceratoconjuntivite seca em cães / Efficacy of cyclosporine and tacrolimus drops in the treatment of keratoconjunctivitis sicca in dogs

O objetivo deste estudo foi avaliar os efeitos do tacrolimo e da ciclosporina na produção lacrimal de cães com ceratoconjuntivite seca (CCS) durante 90 dias. Para tanto, foram utilizados colírios de tacrolimo 0,02% (TcL) e ciclosporina 0,1% (CsA) em 14 cães com CCS. Os animais foram distribuídos em dois grupos e avaliados antes do início do tratamento (T0) e aos 15 (T1), 30 (T2), 45 (T3), 60 (T4), 75 (T5) e 90 (T6) dias após o início do tratamento. Na avaliação clínica, observou-se maior redução da secreção ocular, da opacidade e do edema corneano e da vascularização conjuntival. no grupo tacrolimo. No teste de Schirmer, verificou-se produção basal de 6(4,07 e 5,86(2,85mm/min no TcL e CsA, respectivamente, com aumento significativo da produção lacrimal em ambos os grupos, contudo houve aumento significativo da produção lacrimal a partir dos 15 dias de tratamento no grupo TcL (17,88(5,51mm/min), mas apenas a partir dos 45 dias no grupo CsA (11,86(4,74mm/min). Conclui-se que o uso do colírio tacrolimo aumentou em 68,83% a produção lacrimal em 90 dias de tratamento, comparado com a ciclosporina (56,82%), além de diminuir as manifestações clínicas inerentes à CCS, quando comparado à terapia com ciclosporina.(AU)

The objective of this study was to evaluate the effects of tacrolimus and cyclosporine on the lacrimal production of dogs with ketaroconjunctivitis sicca (KCS) for 90 days. Tacrolimus 0.02% (TcL) and 0.1% cyclosporine (CsA) eye drops were used in 14 dogs with KCS. The animals were randomly assigned to two groups and evaluated before treatment (T0) and at 15 (T1), 30 (T2), 45 (T3), 60 (T4), 75 (T5) and 90 (T6) days after initiation of treatment. Clinical evaluation showed significant reduction of ocular secretion, corneal opacity and edema and conjunctival vascularization in the tacrolimus group. Schirmer test showed basal lacrimal production of 6(4.07 and 5.86(2.85mm/min for TcL and CsA, respectively, with significant increase in lacrimal production in both groups. There was a significant increase in lacrimal production after 15 days of treatment in the TcL group (17.88(5.51mm/min), but only after 45 days in the CsA group (11.86(4.74mm/min). Tacrolimus drops increased lacrimal production in 68.83% after 90 days of treatment, compared to cyclosporine (56.82%), and also reduced clinical manifestations related to KCS when compared to cyclosporine.(AU)

Cyclosporine A attenuates apoptosis and necrosis after ischemia-reperfusion-induced renal injury in transiently hyperglycemic rats

Purpose: To investigate the effects of cyclosporine A on renal ischemia-reperfusion injury during transient hyperglycemia in rats. Methods: In a model of ischemia-reperfusion-induced renal injury and transiently induced hyperglycemia by intraperitoneal injection of glucose, 2.5 g.kg-1, Wistar rats were anesthetized with either isoflurane or propofol and received intravenous cyclosporine A, 5 mg.kg-1, five minutes before reperfusion. Comparison groups were isoflurane and propofol sham groups and isoflurane and propofol ischemia-reperfusion-induced renal injury. Renal tubular cell viability was quantitatively assessed by flow cytometry after cell culture and classified as early apoptosis, necrotic cells, and intact cells. Results: Early apoptosis was significantly higher in isoflurane and propofol anesthetized animals subjected to renal ischemia-reperfusion injury when compared to both cyclosporine A treated and sham groups. Necrosis percentage was significantly higher in propofol-anesthetized animals subjected to renal ischemia-reperfusion injury. The percentage of intact cells was lower in both, isoflurane and propofol anesthetized animals subjected to renal ischemia-reperfusion injury. Conclusion: In a model of ischemia-reperfusion-induced renal injury, cyclosporine A, 5 m.kg-1, administered five minutes before renal reperfusion in rats with acute-induced hyperglycemia under either isoflurano or propofol anesthesia, attenuated early apoptosis and preserved viability in renal tubular cells, regardless of the anesthetic used.(AU)

Eficácia da ciclosporina no controle da dermatite atópica em cães / Efficacy of cyclosporine in the control of atopic dermatitis in dogs

A dermatite atópica é uma dermatopatia inflamatória, pruriginosa, crônica, de origem genética, resultante da perda da função de barreira física da pele e da hiperreatividade à alérgenos ambientais, trofoalérgenos, alérgenos microbianos e a irritantes primários. Este estudo avaliou a eficácia da ciclosporina no controle do prurido e das lesões associadas à dermatite atópica em cães. Selecionaram-se 24 cães com diagnóstico de dermatite atópica baseados nos critérios de Favrot et al. (2010), os quais foram divididos em dois grupos de 12 cães, onde o Grupo 1, recebeu ciclosporina (5mg/kg/vo/24h), e o Grupo 2, foi tratado com prednisona (0,5mg/kg/vo/24h) em doses decrescentes, ambos por 60 dias. Os animais foram continuamente avaliados, e seus escores sintomato-lesionais, baseados na escala de CADESI-03, estabelecidos nos dias 0, 30 e 60. Em adição, os escores de prurido de cada animal, baseado nos critérios de Rybnicek, foram semanalmente avaliados, do dia 0 ao 63. Todos os dados coletados foram analisados pelo teste não paramétrico de Kruskal-Wallis, seguido do teste de Dunn´s e para as análises entre os grupos foi utilizado o teste t, considerado o nível de significância mínimo de 5%. A ciclosporina teve uma eficácia similar, no controle lesional, ao grupo que recebeu prednisona no dia (+30) (p<0,05) e no dia (+60) (p<0,001) do tratamento, em relação ao dia zero. Uma diferença significativa do escore do prurido foi observada nos dias +28, +35, +42, +49, +56 e +63 (p<0,001), e no dia +21 (p<0,01) em relação ao momento inicial do tratamento, porém sua eficácia foi inferior ao Grupo 2, a partir do 42º dia de avaliação, mantendo-se esta diferença nos dias +49, +56 e +63 (p>0,05). Apesar da ciclosporina ter sido menos eficaz no controle do prurido, este se manteve em níveis aceitáveis, e seu uso contínuo não foi associado a efeitos colaterais relevantes.(AU)

Atopic dermatitis is an itchy, chronic inflammatory skin disease of genetic origin, resulting from loss of the physical barrier function of the skin and hyper-reactivity to environmental allergens, trofoallergens, microbial allergens and to primary irritants. The efficacy of cyclosporine in the control of pruritus and lesions associated with atopic dermatitis in dogs was evaluated. Twenty-four dogs with atopic dermatitis were selected, based on Favrot et al.'s criteria (2010). They were divided into two groups of 12 dogs, where Group 1 received cyclosporine (5mg/kg/vo/24h), and Group 2 was treated with prednisone (0.5mg/kg/vo/24h) in decreasing doses, both for 60 days. The animals were continuously evaluated, and theirits lesional symptomatology scores were based on a Cadesi-03 scale, set on days 0, 30 and 60. Pruritus scores of each dog, based on Rybnicek´s criteria, were weekly evaluated, from day 0 to day 63. All collected data were analyzed by the nonparametric Kruskal-Wallis´ test, followed by Dunn's test, and for the analysis between the groups, considered the minimum significance level of 5%, t-test was used. Cyclosporin had similar efficacy in lesional control in the group which received prednisone on day (+30) (p<0.05) and on the day (+60) (p<0.001) of treatment, compared with day zero. A significant difference of the itching score was observed on days +28, +35, +42, +49, +56 and +63 (p<0.001), and on day +21 (p<0.01) when compared to initial treatment. However, its efficacy was lower than Group 2, from 42 days of evaluation on, keeping such difference on days +49, +56 and +63 (p>0.05). Although cyclosporin have been less effective in controlling itching, it remained at acceptable levels, and its continued use was not associated with significant side effects.(AU)

Eficácia da ciclosporina no controle da dermatite atópica em cães / Efficacy of cyclosporine in the control of atopic dermatitis in dogs

A dermatite atópica é uma dermatopatia inflamatória, pruriginosa, crônica, de origem genética, resultante da perda da função de barreira física da pele e da hiperreatividade à alérgenos ambientais, trofoalérgenos, alérgenos microbianos e a irritantes primários. Este estudo avaliou a eficácia da ciclosporina no controle do prurido e das lesões associadas à dermatite atópica em cães. Selecionaram-se 24 cães com diagnóstico de dermatite atópica baseados nos critérios de Favrot et al. (2010), os quais foram divididos em dois grupos de 12 cães, onde o Grupo 1, recebeu ciclosporina (5mg/kg/vo/24h), e o Grupo 2, foi tratado com prednisona (0,5mg/kg/vo/24h) em doses decrescentes, ambos por 60 dias. Os animais foram continuamente avaliados, e seus escores sintomato-lesionais, baseados na escala de CADESI-03, estabelecidos nos dias 0, 30 e 60. Em adição, os escores de prurido de cada animal, baseado nos critérios de Rybnicek, foram semanalmente avaliados, do dia 0 ao 63. Todos os dados coletados foram analisados pelo teste não paramétrico de Kruskal-Wallis, seguido do teste de Dunn´s e para as análises entre os grupos foi utilizado o teste t, considerado o nível de significância mínimo de 5%. A ciclosporina teve uma eficácia similar, no controle lesional, ao grupo que recebeu prednisona no dia (+30) (p<0,05) e no dia (+60) (p<0,001) do tratamento, em relação ao dia zero. Uma diferença significativa do escore do prurido foi observada nos dias +28, +35, +42, +49, +56 e +63 (p<0,001), e no dia +21 (p<0,01) em relação ao momento inicial do tratamento, porém sua eficácia foi inferior ao Grupo 2, a partir do 42º dia de avaliação, mantendo-se esta diferença nos dias +49, +56 e +63 (p>0,05). Apesar da ciclosporina ter sido menos eficaz no controle do prurido, este se manteve em níveis aceitáveis, e seu uso contínuo não foi associado a efeitos colaterais relevantes.(AU)

Atopic dermatitis is an itchy, chronic inflammatory skin disease of genetic origin, resulting from loss of the physical barrier function of the skin and hyper-reactivity to environmental allergens, trofoallergens, microbial allergens and to primary irritants. The efficacy of cyclosporine in the control of pruritus and lesions associated with atopic dermatitis in dogs was evaluated. Twenty-four dogs with atopic dermatitis were selected, based on Favrot et al.'s criteria (2010). They were divided into two groups of 12 dogs, where Group 1 received cyclosporine (5mg/kg/vo/24h), and Group 2 was treated with prednisone (0.5mg/kg/vo/24h) in decreasing doses, both for 60 days. The animals were continuously evaluated, and theirits lesional symptomatology scores were based on a Cadesi-03 scale, set on days 0, 30 and 60. Pruritus scores of each dog, based on Rybnicek´s criteria, were weekly evaluated, from day 0 to day 63. All collected data were analyzed by the nonparametric Kruskal-Wallis´ test, followed by Dunn's test, and for the analysis between the groups, considered the minimum significance level of 5%, t-test was used. Cyclosporin had similar efficacy in lesional control in the group which received prednisone on day (+30) (p<0.05) and on the day (+60) (p<0.001) of treatment, compared with day zero. A significant difference of the itching score was observed on days +28, +35, +42, +49, +56 and +63 (p<0.001), and on day +21 (p<0.01) when compared to initial treatment. However, its efficacy was lower than Group 2, from 42 days of evaluation on, keeping such difference on days +49, +56 and +63 (p>0.05). Although cyclosporin have been less effective in controlling itching, it remained at acceptable levels, and its continued use was not associated with significant side effects.(AU)

Eficácia da ciclosporina no controle da dermatite atópica em cães

ABSTRACT: Atopic dermatitis is an itchy, chronic inflammatory skin disease of genetic origin, resulting from loss of the physical barrier function of the skin and hyper-reactivity to environmental allergens, trofoallergens, microbial allergens and to primary irritants. The efficacy of cyclosporine in the control of pruritus and lesions associated with atopic dermatitis in dogs was evaluated. Twenty-four dogs with atopic dermatitis were selected, based on Favrot et al.s criteria (2010). They were divided into two groups of 12 dogs, where Group 1 received cyclosporine (5mg/kg/vo/24h), and Group 2 was treated with prednisone (0.5mg/kg/vo/24h) in decreasing doses, both for 60 days. The animals were continuously evaluated, and theirits lesional symptomatology scores were based on a Cadesi-03 scale, set on days 0, 30 and 60. Pruritus scores of each dog, based on Rybnicek´s criteria, were weekly evaluated, from day 0 to day 63. All collected data were analyzed by the nonparametric Kruskal-Wallis´ test, followed by Dunns test, and for the analysis between the groups, considered the minimum significance level of 5%, t-test was used. Cyclosporin had similar efficacy in lesional control in the group which received prednisone on day (+30) (p 0.05) and on the day (+60) (p 0.001) of treatment, compared with day zero. A significant difference of the itching score was observed on days +28, +35, +42, +49, +56 and +63 (p 0.001), and on day +21 (p 0.01) when compared to initial treatment. However, its efficacy was lower than Group 2, from 42 days of evaluation on, keeping such difference on days +49, +56 and +63 (p>0.05). Although cyclosporin have been less effective in controlling itching, it remained at acceptable levels, and its continued use was not associated with significant side effects.

RESUMO: A dermatite atópica é uma dermatopatia inflamatória, pruriginosa, crônica, de origem genética, resultante da perda da função de barreira física da pele e da hiperreatividade à alérgenos ambientais, trofoalérgenos, alérgenos microbianos e a irritantes primários. Este estudo avaliou a eficácia da ciclosporina no controle do prurido e das lesões associadas à dermatite atópica em cães. Selecionaram-se 24 cães com diagnóstico de dermatite atópica baseados nos critérios de Favrot et al. (2010), os quais foram divididos em dois grupos de 12 cães, onde o Grupo 1, recebeu ciclosporina (5mg/kg/vo/24h), e o Grupo 2, foi tratado com prednisona (0,5mg/kg/vo/24h) em doses decrescentes, ambos por 60 dias. Os animais foram continuamente avaliados, e seus escores sintomato-lesionais, baseados na escala de CADESI-03, estabelecidos nos dias 0, 30 e 60. Em adição, os escores de prurido de cada animal, baseado nos critérios de Rybnicek, foram semanalmente avaliados, do dia 0 ao 63. Todos os dados coletados foram analisados pelo teste não paramétrico de Kruskal-Wallis, seguido do teste de Dunn´s e para as análises entre os grupos foi utilizado o teste t, considerado o nível de significância mínimo de 5%. A ciclosporina teve uma eficácia similar, no controle lesional, ao grupo que recebeu prednisona no dia (+30) (p 0,05) e no dia (+60) (p 0,001) do tratamento, em relação ao dia zero. Uma diferença significativa do escore do prurido foi observada nos dias +28, +35, +42, +49, +56 e +63 (p 0,001), e no dia +21 (p 0,01) em relação ao momento inicial do tratamento, porém sua eficácia foi inferior ao Grupo 2, a partir do 42º dia de avaliação, mantendo-se esta diferença nos dias +49, +56 e +63 (p>0,05). Apesar da ciclosporina ter sido menos eficaz no controle do prurido, este se manteve em níveis aceitáveis, e seu uso contínuo não foi associado a efeitos colaterais relevantes.

The effects of propolis on sperm quality, reproductive organs and testicular antioxidant status of male rats treated with cyclosporine-A

This study was designed to determine the effects of propolis on the quality of sperm and reproductive organs in male rats treated with cyclosporine-A. In this study, 24 male Sprague-Dawley rats (280-300 g BW) at 8-10 weeks of age were used. The rats were randomly divided into control and 3 treatment groups. Each rat was placed into a cage. During 21 days (experimental period), Group 1 served as control group; Group 2 (CsA) was given 15 mg/kg BW/day of CsA by subcutaneously; Group 3 (P) was given 100 mg/kg BW/day of propolis by gavage; Group 4 (CsA+P) was given 15 mg/kg BW/day of CsA subcutaneously and 100 mg/kg BW/day of propolis by gavage. Administration of CsA to rats decreased sperm motility (P < 0.01) and sperm concentration (P < 0.01), and it increased total abnormal sperm rates (P < 0.05) as compared with the control group. Significant improvements were observed in the sperm motility (P < 0.01) and total abnormal sperm rates (P < 0.05) in CsA+P group. No significant differences were observed in the weights of right and left testes among all groups. The weight values of right and left epididymis were found similar to each other in CsA administrated groups. Seminal vesicle (P < 0.01) and prostat glands weights (P < 0.01) were significantly higher in CsA+P group than CsA group. As a result, it was determined that oral supplementation of 100 mg/kg of propolis had amendatory effect on the quality of sperm and reproductive organs treated with CsA administered rats. CsA treatment caused a significant increase in MDA level (P < 0.01) and significant decreases (P < 0.01) in GSH level and CAT activity when compared with the control group. Ingestion of propolis by CsA-treated rats significantly decreased the MDA level and significantly increased the GSH level when compared with the CsA alone group (P < 0.01).

The effects of propolis on sperm quality, reproductive organs and testicular antioxidant status of male rats treated with cyclosporine-A

This study was designed to determine the effects of propolis on the quality of sperm and reproductive organs in male rats treated with cyclosporine-A. In this study, 24 male Sprague-Dawley rats (280-300 g BW) at 8-10 weeks of age were used. The rats were randomly divided into control and 3 treatment groups. Each rat was placed into a cage. During 21 days (experimental period), Group 1 served as control group; Group 2 (CsA) was given 15 mg/kg BW/day of CsA by subcutaneously; Group 3 (P) was given 100 mg/kg BW/day of propolis by gavage; Group 4 (CsA+P) was given 15 mg/kg BW/day of CsA subcutaneously and 100 mg/kg BW/day of propolis by gavage. Administration of CsA to rats decreased sperm motility (P < 0.01) and sperm concentration (P < 0.01), and it increased total abnormal sperm rates (P < 0.05) as compared with the control group. Significant improvements were observed in the sperm motility (P < 0.01) and total abnormal sperm rates (P < 0.05) in CsA+P group. No significant differences were observed in the weights of right and left testes among all groups. The weight values of right and left epididymis were found similar to each other in CsA administrated groups. Seminal vesicle (P < 0.01) and prostat glands weights (P < 0.01) were significantly higher in CsA+P group than CsA group. As a result, it was determined that oral supplementation of 100 mg/kg of propolis had amendatory effect on the quality of sperm and reproductive organs treated with CsA administered rats. CsA treatment caused a significant increase in MDA level (P < 0.01) and significant decreases (P < 0.01) in GSH level and CAT activity when compared with the control group. Ingestion of propolis by CsA-treated rats significantly decreased the MDA level and significantly increased the GSH level when compared with the CsA alone group (P < 0.01).(AU)

Effect of cyclosporine on liver regeneration in partial hepatectomized rats

PURPOSE: To evaluate the influence of the cyclosporine in liver regeneration in rats submitted to an experimental model of 70% hepatectomy. METHODS: Forty male rats were randomly divided in four subgroups (C.24h, C.7d, E.24h, E.7d), according to the drug used and the day of sacrifice (24 hours and 7 days). Cyclosporine (10mg/Kg/day) was given to the study subgroup and 1 ml of 0.9% sodium chloride was to the control subgroup. Resection of left lateral lobe and median lobe performing 70% of liver mass. During the animals death, KWON formula was applied. Counting of mitotic figures and percentage of positive nucleus with PCNA and Ki-67 were evaluated. RESULTS: In the 2nd, 4th PO and death days, E.7d lose more weight than C.7d. Regarding to the KWON formula, the C.7d regenerated more than the C.24h and the same with the E.7d. Comparing between the groups, only E7d subgroup was statistically significant compared with C.7d, showing the stimulating effect of cyclosporine in liver regeneration. Immunohistochemestry had significant results between the study subgroups. The mitotic index revealed statistical differences in the control subgroups. CONCLUSION: Cyclosporine, in spite of being an immunosuppressive drug, has a positive effect in liver regeneration, although reduce the animals body weight.(AU)

Evaluation of the clinical efficacy of cyclosporine in atopic dogs treatment / Avaliação da eficácia da ciclosporina no tratamento de cães atópicos

Atopic dermatitis (AD) is an inflammatory, pruritic and chronic allergic skin disease. It is recognized as the secondmost common allergic skin disease of dogs, after flea allergy. Pruritus is the predominant sign of canine AD, and it affects a variety of areas of the body, leading to intense suffering in both the animal and its owner. The long-term use of glucocorticoid therapy can be devastating because of its numerous side effects and secondary diseases. Cyclosporine (CsA) has been considered a good therapeutic option to treat canine AD. CsA inhibits the activation of cells that initiate the cutaneous immune response (Langerhans cells and lymphocytes) and that mediate allergic reactions (mast cells and eosinophils). It also decreases the release of histamine and other cytokines. The objective of this study was to analyze the efficacy of CsA (5 mg/kg, SID for 60 days) to reduce skin lesions and pruritus in 21 atopic dogs using CADESI-03 and two scales to quantify the levels of body itching. This immunomodulatory therapy was considered to be an effective treatment for atopic dogs because it reduced skin lesions by 70% after 60 days of therapy. During that period, there was a 52.6% reduction of body itching as assessed via a verbal numeric scale, and there was a significant reduction of body itching on a qualitative scale, as the maximal levels of pruritus (“three” and “four”) were hardly observed after immunomodulatory therapy. CsA was effective and safe in the treatment of canine atopic dermatitis.(AU)

A atopia ou dermatite atópica é uma doença inflamatória pruriginosa, crônica e recorrente reconhecida como a segunda alergopatia mais comum, estando aquém apenas da dermatite alérgica à picada de pulgas. Esta doença é caracterizada pela presença exacerbada de prurido corpóreo, infringindo sofrimento ao paciente e desalentando seu proprietário. Por se tratar de uma doença de longo decurso, o tratamento com glicocorticoides pode causar diversos efeitos adversos, além de doenças mais graves. Como alternativa ao tratamento de cães atópicos, a ciclosporina (CsA) acaba tornando-se uma boa opção terapêutica. A CsA inibe as funções das células que iniciam a resposta imunológica (células de Langerhans e linfócitos) e das células que efetuam a resposta alérgica (mastócitos e eosinófilos) e, também, diminui a liberação de histamina e de várias citocinas. O objetivo do presente estudo incluiu a: análise da eficácia da CsA (5mg/kg, SID durante 60 dias) na redução de lesões corpóreas e do prurido com auxílio do CADESI-03 e de duas escalas de prurido corpóreo. A CsA mostrou-se eficaz no tratamento da dermatite atópica canina pois reduziu as lesões corpóreas em 70% após 60 dias de terapia. Nesse mesmo período ocorreu redução da intensidade do prurido corpóreo em 52,6%, avaliado através da escala numérica verbal; e observou-se redução significativa na escala qualitativa de prurido corpóreo, uma vez que os níveis máximos de prurido (“três” e “quatro”) quase não foram observados após a terapia imunomodulatória. A CsA mostrou-se eficaz no tratamento da dermatite atópica canina.(AU)

Efeitos do uso tópico do conservante Cloreto de Benzalcônio e Ciclosporina na conjuntiva de coelhos - Estudo Histomorfométrico e Imuno-histoquímico

A presente dissertação de mestrado buscou contribuir com informações sobre os efeitos tóxicos do conservante cloreto de benzalcônio (BAK) tópico na conjuntiva de coelhos e o possível efeito protetor da ciclosporina 0,05% nessa toxicidade, particularmente no que diz respeito à ação dessas drogas sobre as células caliciformes, fibrose tecidual, inflamação do endotélio vascular, estimulação da angiogênese, além da ativação de linfócitos T reativos. O primeiro capítulo aborda o estudo histomorfométrico da conjuntiva em amostras coradas com Hematoxilina e Eosina (HE) e Ácido periódico de Schiff (PAS) e a análise da ação do BAK unicamente sobre as células caliciformes e a neovascularização do tecido inflamado, assim como a ação da ciclosporina sobre esses parâmetros. O segundo capítulo aborda a avaliação imuno-histoquímica das alterações induzidas pelo BAK e a possível inibição dessas alterações pela ciclosporina, analisando a indução de fibrose tecidual pela expressão de colágeno tipo I e III, a expressão de vasos sanguíneos reativos por meio do anticorpo anti-VCAM-1 e a expressão de linfócitos T reativos por meio do anticorpo anti-CD45RO. O objetivo do estudo foi oferecer uma alternativa de tratamento que atenue os efeitos deletérios da inflamação crônica causada pelos conservantes presentes em colírios no tratamento contínuo do glaucoma (mais especificamente o BAK), comprovando que a ciclosporina possui ação positiva em alguns dos parâmetros estudados.

This dissertation sought to investigate the toxic effects of topical benzalkonium chloride (BAK) on the conjunctiva of rabbits and a possible protective effect for the use of cyclosporine 0.05% against this toxicity, particularly with respect to the action of these drugs on goblet cells, tissue fibrosis, inflammation of vascular endothelium, stimulation of angiogenesis, and activation of reactive T lymphocytes. The first chapter is a classic histomorphometric study of the conjunctiva in samples stained with Hematoxylin and Eosin (HE) and PAS and the analysis of the BAK activity only on goblet cells and the neovascularization of the inflamed tissue, as well as the action of cyclosporine on these parameters. The second chapter is an immunohistochemical evaluation of BAK-induced changes and the possible inhibition of these alterations by cyclosporine, analyzing the induction of tissue fibrosis by the expression of collagen type I and III, the expression of reactive blood vessels by anti- VCAM-1 and the expression of reactive T lymphocytes by the anti-CD45RO antibody. The objective of the study was to investigate and perhaps to offer a treatment alternative that would alleviate the deleterious effects of chronic inflammation caused by preservatives present in eye drops in the continuous treatment of glaucoma (more specifically BAK), proving that cyclosporine has a positive preventing activity in some of the toxic effects studied.

EFICÁCIA DA CICLOSPORINA MANIPULADA NO CONTROLE DA DERMATITE ATÓPICA EM CÃES

Em cães a dermatite atópica (DA) é uma dermatopatia crônica de caráter inflamatório e pruriginoso, associada à predisposição genética. Os sinais clínicos estão associados comumente com direcionamento de imunoglobulinas do tipo E (IgE) a alérgenos ambientais desencadeando uma hiper-reatividade cutânea e refletindo na apresentação clínica da doença. O diagnóstico é clínico, e presumido pelos critérios estabelecidos por Favrot (2010). O controle da DA é multifatorial, abrange minimização de agentes precipitadores de prurido, reestruturação da barreira cutânea com uso de hidratantes tópicos, e o controle do prurido primário são imprescindíveis no manejo clínico. Medicações orais são utilizadas com o objetivo de minimizar os sinais da DA, os glicocorticoides apresentam alta eficácia no controle do prurido e redução da inflamação, em contrapartida responsável por efeitos colaterais multissistêmicos com o uso prolongado. A ciclosporina, um inibidor da calcineurina é a medicação de eleição para minimizar prurido e controlar lesões em longo prazo, com efeitos colaterais mínimos. O objetivo deste estudo foi avaliar a eficácia da ciclosporina manipulada no controle do prurido e lesões associadas à dermatite atópica em cães. Foram selecionados 24 cães independente de gênero, raça e idade, diagnosticados com DA baseados nos critérios de Favrot. Estes foram divididos em dois grupos: 1. Grupo Ciclosporina manipulada formado por 14 cães, que receberam ciclosporina manipulada, sem flavorizantes na dose de 5 mg/kg/vo/24h em jejum prévio de 2 horas, juntamente com prednisolona na dose de 0,5 mg/kg/vo/24h durante sete dias, seguido de 0,5 mg/kg/vo, a cada 48 horas por mais sete dias. Após 14 dias, foi mantida a monoterapia com ciclosporina por 76 dias, totalizando 90 dias de tratamento. 2. Grupo glicocorticoide, composto por 10 cães, que receberam prednisolona (0,5 mg/kg/vo/24h), durante sete dias, seguido de 0,5 mg/kg/vo/48h, por 14 dias e em seguida se manteve a dose de 0,5 mg/kg/vo/72h durante 69 dias, totalizando 3 meses de tratamento. Os cães foram submetidos à avaliação para obtenção de escores pela escala de CADESI-03 e de prurido pela escala de RYBNICEK nos dias 0, 15, 30, 45, 60, 75 e 90 de tratamento. A eficácia foi analisada pelo teste de Mann Whitney para as comparações entre os grupos, e Kruskal-Wallis seguido do teste de Dunns para comparações dentro dos grupos. No grupo 1, houve redução dos sinais clínicos, nos dias 60, 75 e 90 de tratamento (p< 0,01) em relação ao dia zero do tratamento. Foi observada uma redução inicial do prurido até o dia 15 (p<0,01) e posteriormente no dia 60, 75 e 90 (p<0,001). Quando se compararam os dois grupos em relação à involução lesional, uma resposta significativa estava presente nos dias 60 e 90 de observação (p<0,01). Em relação ao escore de prurido, este diminuiu de forma significativa no grupo 1 em relação ao grupo 2 a partir do dia 60 e se manteve até os 90 dias de tratamento. Efeitos colaterais se limitaram a êmese em 3/14 (21,42%) cães, que foi autolimitante. A ciclosporina manipulada se mostrou eficaz no controle das lesões e prurido associados à dermatite atópica em cães.

In dogs atopic dermatitis (AD) is a chronic inflammatory and pruritic skin disease, associated with genetic predisposition. Clinical signs are commonly associated with immunoglobulins type E (IgE) targeting of to environmental allergens triggering a cutaneous hyperreactivity and reflecting on the clinical presentation of the disease. The diagnosis is clinical, and presumed by Favros criteria (2010). The control of DA is multifactorial, encompasses minimization of the pruritus, precipitators agents, restructuring the skin barrier with use of moisturizers topics, and control of primary pruritus are essential in the clinical management. Oral medications are used in order to minimize the DA signals, glucocorticoids have high efficacy in controlling the pruritus and reduce inflammation, in turn responsible for multisystem side effects with prolonged use. Cyclosporine, a calcineurin inhibitor is the preferred medication to minimize itching and lesions in the long term control, with minimal side effects. The objective of this study was to evaluate the efficacy of compounded cyclosporine manipulated to control the pruritus and lesions associated with atopic dermatitis in dogs. A total of 24 dogs regardless of gender, breed and age, diagnosed with AD based on Favros criteria. These were divided into two groups: 1. Group Compouded cyclosporine consists of 14 dogs that received compouded cyclosporine without flavoring at a dose of 5 mg / kg / vo / 24h fasting for 2 hours with prednisolone at the dose of 0, 5 mg / kg / vo / 24 for seven days followed by 0.5 mg / kg / orally every 48 hours for seven days. After 14 days, kept monotherapy with cyclosporine for 76 days, totaling 90 days' treatment. 2. glucocorticoid group consisting of 10 dogs that received prednisolone (0.5 mg / kg / vo / 24h) for seven days followed by 0.5 mg / kg / vo / 48h for 14 days and then maintained a dose of 0.5 mg / kg / vo / 72h for 69 days, totaling 3 months of treatment. The dogs were evaluated to obtain scores by scale CADESI-03 and pruritus by RYBNICEK scale on days 0, 15, 30, 45, 60, 75 and 90 of treatment. Efficacy was analyzed by Mann Whitney test for comparisons between groups and Kruskal-Wallis followed by Dunn's test for comparisons within groups. In Group 1, reduction in clinical signs on days 60, 75 and 90 of treatment (p <0.01) compared to day zero treatment. We observed an initial reduction of pruritus by day 15 (p <0.01) and subsequently on day 60, 75 and 90 (p <0.001). When comparing the two groups regarding lesion involution, a significant response was present in 60 and 90 days of observation (p <0.01). Regarding the pruritus score, it decreased significantly in group 1 than in group 2 from day 60 and remained until 90 days of treatment. Side effects were limited to vomiting in 3/14 (21.42%) dogs, which was self-limiting. The compouded cyclosporine is effective in controlling the lesions and pruritus associated with atopic dermatitis in dogs.

Cyclosporine action on kidneys of rats submitted to normothermic ischaemia and reperfusion / Ação da ciclosporina em rins de ratos submetidos à isquemia normotérmica e reperfusão

PURPOSE: To verify if rat kidneys lesioned by ischaemia followed by reperfusion are affected by cyclosporine A (CsA). METHODS: Male Wistar rats were randomly divided into three groups, control (GS) and experimental (G1 and G2). G1 was subdivided in two: G1A composed of animals submitted to 60 minutes ischaemia and G1C with the same ischaemic procedure associated to 20 mg/kg/day CsA. Group G2 was subdivided and treated in the same way as G1 except that ischaemia was applied only for 40 minutes. Clamping the left renal artery followed by right side nephrectomy induced kidney ischaemia. Serum urea and creatinine were quantified on the day of surgery (D0) and in the following day (D1). Twenty four hours after reperfusion the left kidney was removed and histologically analyzed. RESULTS: Group GS had normal values for urea and creatinine both on D0 and D1 and did not show structural alterations. Renal function was not significantly different when G2C was compared to GS (p>0.05). Tissue lesions were smaller in G2C than in the other groups. CONCLUSIONS: Renal function was protected by CsA, which also reduced tissue lesions in the kidneys of rats submitted to 40 minutes ischaemia.(AU)

OBJETIVO: Verificar se a ciclosporina A (CsA) afeta a lesão provocada pela isquemia seguida de reperfusão em rins de ratos. MÉTODOS: Ratos Wistar machos foram separados em grupos: 1 grupo controle (GS) e 2 grupos experimentais (G1 e G2). O G1 foi dividido em G1A - isquemia de 60 minutos; e G1C - isquemia de 60 minutos associada a 20 mg/kg/dia de CsA. O G2 foi dividido em G2C semelhante ao G1, exceto pelo tempo de isquemia de 40 minutos. A isquemia renal foi provocada pelo pinçamento da artéria renal esquerda, após o procedimento, foi realizada a nefrectomia direita. Dosagem de uréia e creatinina séricos foram feitos no dia da cirurgia (D0) e no dia seguinte (D1). Após 24 horas de reperfusão o rim esquerdo foi removido para análise histológica. RESULTADOS: No GS não foram observados alterações de uréia e creatinina em D0 e D1, tampouco alterações estruturais. A comparação entre GS e G2C não mostrou diferença na função renal (p>0,05); o grau de lesão tecidual foi menor em G2C do que nos demais grupos experimentais. CONCLUSÃO: A CsA protegeu a função renal e reduziu a lesão tecidual em rins de ratos submetidos a 40 minutos de isquemia.(AU)

Dermatite idiopática facial do gato persa: relato de caso / Face dermatitis idiopathic in a persian cat: a case report

A dermatite facial Idiopática do gato Persa (DFIGP) é uma dermatite facial rara, progressiva e sem etiologiadefinida, apresentando maior incidência em filhotes e adultos jovens. O presente trabalho descreve um caso de DFIGP em um gato persa, de 2 anos de idade. Após a realização de exames, o tratamento foi iniciado com prednisolona, cefalexina, vermifugação em dose única e fipronil spray. Com intuito de fazer um diagnóstico diferencial, realizou-se dieta de eliminação com uma ração hipoalergênica comercial por12 semanas. Após 10 dias do término do tratamento o paciente não apresentava melhora significativa doquadro. Optou-se então por iniciar um tratamento com ciclosporina, lavagem com xampu constituído por 2% de ácido salicílico e 2% de enxofre, e posterior aplicação de uma pomada com nistatina, sulfato de neomicina, tiostrepton e acetonil triancinolona. O gato demonstrou melhora acentuada do quadro com 10 dias do novo tratamento e remissão do quadro ao fim do tratamento, no entanto, após 30 dias sem tratamento, o animal voltou a apresentar o quadro clínico. Conclui-se que DFIGP persiste como umaenfermidade sem tratamento eficiente descrito. (AU)

Idiopathic facial dermatitis of the Persian cat (DFIGP) is a rare, progressive disease of unknown etiology. It has an higher incidence in puppies and young adults. This paper describes a case of DFIGPin a Persian cat, 2 years old. It was initially treated with prednisolone, cephalexin and fipronil spray.It was also prescribed an elimination diet with a commercial hypoallergenic diet for 12 weeks in orderto make a differential diagnosis. No significant improvent was observed after this treatment. It was then decided to start a treatment with cyclosporine and shampoo consisting of 2% salicylic acid and 2% sulfur. Addicionally it was prescribed the topical application of an ointment with nystatin, neomycin sulfate, triamcinolone tiostrepton and acetonyl. The patient showed marked improvement after 10 days of this new treatment and complete remission after 40 days of treatment, however, after30 days without treatment, the cat presented the previous skin injury. It is concluded that DFIGP isa persistent disease without effective treatment. (AU)

Dermatite idiopática facial do gato persa: relato de caso / Face dermatitis idiopathic in a persian cat: a case report

A dermatite facial Idiopática do gato Persa (DFIGP) é uma dermatite facial rara, progressiva e sem etiologiadefinida, apresentando maior incidência em filhotes e adultos jovens. O presente trabalho descreve um caso de DFIGP em um gato persa, de 2 anos de idade. Após a realização de exames, o tratamento foi iniciado com prednisolona, cefalexina, vermifugação em dose única e fipronil spray. Com intuito de fazer um diagnóstico diferencial, realizou-se dieta de eliminação com uma ração hipoalergênica comercial por12 semanas. Após 10 dias do término do tratamento o paciente não apresentava melhora significativa doquadro. Optou-se então por iniciar um tratamento com ciclosporina, lavagem com xampu constituído por 2% de ácido salicílico e 2% de enxofre, e posterior aplicação de uma pomada com nistatina, sulfato de neomicina, tiostrepton e acetonil triancinolona. O gato demonstrou melhora acentuada do quadro com 10 dias do novo tratamento e remissão do quadro ao fim do tratamento, no entanto, após 30 dias sem tratamento, o animal voltou a apresentar o quadro clínico. Conclui-se que DFIGP persiste como umaenfermidade sem tratamento eficiente descrito.

Idiopathic facial dermatitis of the Persian cat (DFIGP) is a rare, progressive disease of unknown etiology. It has an higher incidence in puppies and young adults. This paper describes a case of DFIGPin a Persian cat, 2 years old. It was initially treated with prednisolone, cephalexin and fipronil spray.It was also prescribed an elimination diet with a commercial hypoallergenic diet for 12 weeks in orderto make a differential diagnosis. No significant improvent was observed after this treatment. It was then decided to start a treatment with cyclosporine and shampoo consisting of 2% salicylic acid and 2% sulfur. Addicionally it was prescribed the topical application of an ointment with nystatin, neomycin sulfate, triamcinolone tiostrepton and acetonyl. The patient showed marked improvement after 10 days of this new treatment and complete remission after 40 days of treatment, however, after30 days without treatment, the cat presented the previous skin injury. It is concluded that DFIGP isa persistent disease without effective treatment.